(2C) Chapter 5: Triglyceride-lowering treatment in adults 5.1: In adults with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (2D) Chapter 6: Triglyceride-lowering treatment in children 6.1: In children with CKD (including those treated with chronic dialysis or kidney transplantation) and hypertriglyceridemia, we suggest that therapeutic lifestyle changes be advised. (2D) summary of recommendation statements Quick summary of the KDIGO recommendations for lipid-lowering treatment in adults with CKD (a) Rule out remediable causes of secondary dyslipidemia. (b) Establish the indication of treatment (YES or NO) and select agent and dose. (c) Treat according to a fire-and-forget strategy: do not measure LDL-C unless the results would alter management. Upon first presentation to establish the diagnosis of CKD, the nephrologist will obtain a full lipid profile as part of routine care. In case of referral and to confirm the CKD diagnosis, a full lipid profile may already be available. Results of the lipid profile should be used together with other clinical data to rule out remediable causes of secondary dyslipidemia. If excluded, the nephrologist will establish whether statin treatment is indicated (YES or NO) based on underlying cardiovascular risk. If the level of risk suggests that statin treatment is indicated, she/he will select a dose of a statin (Table 4) that is available in her/his country and has been tested for safety in people with CKD. Contemporary practice and other clinical practice guidelines emphasize the use of targets for LDL-C (e.g., 1.8 or 2.6 mmol/l [70 or 100 mg/dl]), which require repeated measurements of LDL-C and treatment escalation with higher doses of statin or initiation of combination lipid-lowering therapy ( treat-to-target strategy) when the LDL-C target is not met. 